Neera Nathan1, Ji-an Wang2, Shaowei Li2, Edward W Cowen3, Mary Haughey4, Joel Moss4, Thomas N Darling5. 1. Department of Dermatology, Uniformed Services University of Health Sciences, Bethesda, Maryland; Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 2. Department of Dermatology, Uniformed Services University of Health Sciences, Bethesda, Maryland. 3. Dermatology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland. 4. Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 5. Department of Dermatology, Uniformed Services University of Health Sciences, Bethesda, Maryland. Electronic address: thomas.darling@usuhs.edu.
Abstract
BACKGROUND: Oral mechanistic target of rapamycin inhibitors have been shown to reduce visceral tumor volume in patients with tuberous sclerosis complex (TSC). OBJECTIVE: We sought to evaluate the cutaneous response to oral sirolimus in patients with TSC and an indication for systemic treatment, including long-term effects. METHODS: A retrospective analysis of 14 adult patients with TSC prescribed sirolimus to treat lymphangioleiomyomatosis was performed. Serial photographs of angiofibromas, shagreen patches, and ungual fibromas taken before, during, and after the treatment period were blinded, then assessed using the Physician Global Assessment of Clinical Condition (PGA). Microscopic and molecular studies were performed on skin tumors harvested before and during treatment. RESULTS: Sirolimus significantly improved angiofibromas (median treatment duration 12 months; median PGA score 4.5 [range 1.5-5]; Wilcoxon signed rank test, P = .018) and shagreen patches (median treatment duration 10 months; median PGA score 4.5 [range 3.5-5]; Wilcoxon signed rank test, P = .039), whereas ungual fibromas improved in some patients (median treatment duration 6.5 months; median PGA score 4.66 [range 2.75-5]; Wilcoxon signed rank test, P = .109). Clinical, immunohistochemical, or molecular evidence of resistance was not observed (range 5-64 months of treatment). LIMITATIONS: This was a retrospective analysis limited to adult women with lymphangioleiomyomatosis. CONCLUSION: Oral sirolimus is an effective long-term therapy for TSC skin tumors, particularly angiofibromas, in patients for whom systemic treatment is indicated. Published by Elsevier Inc.
BACKGROUND: Oral mechanistic target of rapamycin inhibitors have been shown to reduce visceral tumor volume in patients with tuberous sclerosis complex (TSC). OBJECTIVE: We sought to evaluate the cutaneous response to oral sirolimus in patients with TSC and an indication for systemic treatment, including long-term effects. METHODS: A retrospective analysis of 14 adult patients with TSC prescribed sirolimus to treat lymphangioleiomyomatosis was performed. Serial photographs of angiofibromas, shagreen patches, and ungual fibromas taken before, during, and after the treatment period were blinded, then assessed using the Physician Global Assessment of Clinical Condition (PGA). Microscopic and molecular studies were performed on skin tumors harvested before and during treatment. RESULTS:Sirolimus significantly improved angiofibromas (median treatment duration 12 months; median PGA score 4.5 [range 1.5-5]; Wilcoxon signed rank test, P = .018) and shagreen patches (median treatment duration 10 months; median PGA score 4.5 [range 3.5-5]; Wilcoxon signed rank test, P = .039), whereas ungual fibromas improved in some patients (median treatment duration 6.5 months; median PGA score 4.66 [range 2.75-5]; Wilcoxon signed rank test, P = .109). Clinical, immunohistochemical, or molecular evidence of resistance was not observed (range 5-64 months of treatment). LIMITATIONS: This was a retrospective analysis limited to adult women with lymphangioleiomyomatosis. CONCLUSION: Oral sirolimus is an effective long-term therapy for TSC skin tumors, particularly angiofibromas, in patients for whom systemic treatment is indicated. Published by Elsevier Inc.
Authors: Joyce M C Teng; Edward W Cowen; Mari Wataya-Kaneda; Elizabeth S Gosnell; Patricia M Witman; Adelaide A Hebert; Greg Mlynarczyk; Keyoumars Soltani; Thomas N Darling Journal: JAMA Dermatol Date: 2014-10 Impact factor: 10.282
Authors: Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Ali Amin-Mansour; Amaro Taylor-Weiner; Mara Rosenberg; Nathanael Gray; Justine A Barletta; Yanan Guo; Scott J Swanson; Daniel T Ruan; Glenn J Hanna; Robert I Haddad; Gad Getz; David J Kwiatkowski; Scott L Carter; David M Sabatini; Pasi A Jänne; Levi A Garraway; Jochen H Lorch Journal: N Engl J Med Date: 2014-10-09 Impact factor: 91.245
Authors: Shaowei Li; Fumiko Takeuchi; Ji-An Wang; Qingyuan Fan; Toshi Komurasaki; Eric M Billings; Gustavo Pacheco-Rodriguez; Joel Moss; Thomas N Darling Journal: Proc Natl Acad Sci U S A Date: 2008-02-21 Impact factor: 11.205
Authors: D Mark Davies; Petrus J de Vries; Simon R Johnson; Deborah L McCartney; Jane A Cox; Andreas L Serra; Peter C Watson; Christopher J Howe; Tim Doyle; Kate Pointon; Justin J Cross; Anne E Tattersfield; J Chris Kingswood; Julian R Sampson Journal: Clin Cancer Res Date: 2011-04-27 Impact factor: 12.531
Authors: Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss Journal: Am J Respir Cell Mol Biol Date: 2018-06 Impact factor: 6.914
Authors: Michelle A Bongiorno; Neera Nathan; Oyetewa Oyerinde; Ji-An Wang; Chyi-Chia Richard Lee; G Thomas Brown; Joel Moss; Thomas N Darling Journal: JAMA Dermatol Date: 2017-07-01 Impact factor: 10.282
Authors: Neera Nathan; Kim M Keppler-Noreuil; Leslie G Biesecker; Joel Moss; Thomas N Darling Journal: Dermatol Clin Date: 2017-01 Impact factor: 3.478
Authors: Sally E Dickinson; Jaroslav Janda; Jane Criswell; Karen Blohm-Mangone; Erik R Olson; Zhonglin Liu; Christy Barber; Emanuel F Petricoin; Valerie S Calvert; Janine Einspahr; Jesse E Dickinson; Steven P Stratton; Clara Curiel-Lewandrowski; Kathylynn Saboda; Chengcheng Hu; Ann M Bode; Zigang Dong; David S Alberts; G Timothy Bowden Journal: Cancer Prev Res (Phila) Date: 2016-01-22
Authors: Samy L Habib; Noor Y Al-Obaidi; Maciej Nowacki; Katarzyna Pietkun; Barbara Zegarska; Tomasz Kloskowski; Wojciech Zegarski; Tomasz Drewa; Edward A Medina; Zhenze Zhao; Sitai Liang Journal: J Cancer Date: 2016-07-21 Impact factor: 4.207